These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17071479)

  • 1. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.
    Savaşan S; Buck S; Raimondi SC; Becton DL; Weinstein H; Chang M; Ravindranath Y
    Leuk Lymphoma; 2006 Oct; 47(10):2076-83. PubMed ID: 17071479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype.
    Wang L; Peters JM; Fuda F; Li L; Karandikar NJ; Koduru P; Wang HY; Chen W
    Cytometry B Clin Cytom; 2015; 88(4):244-52. PubMed ID: 25361478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
    Langebrake C; Creutzig U; Reinhardt D
    Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
    Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
    PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
    Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
    Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD36 - a marker for drug sensitive acute megakaryoblastic leukemia.
    Gurbuxani S
    Leuk Lymphoma; 2006 Oct; 47(10):2004-5. PubMed ID: 17071466
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.
    Hama A; Muramatsu H; Makishima H; Sugimoto Y; Szpurka H; Jasek M; O'Keefe C; Takahashi Y; Sakaguchi H; Doisaki S; Shimada A; Watanabe N; Kato K; Kiyoi H; Naoe T; Kojima S; Maciejewski JP
    Br J Haematol; 2012 Feb; 156(3):316-25. PubMed ID: 22122069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS).
    Pelleri MC; Piovesan A; Caracausi M; Berardi AC; Vitale L; Strippoli P
    BMC Med Genomics; 2014 Dec; 7():63. PubMed ID: 25476127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia.
    Qi H; Mao Y; Cao Q; Sun X; Kuai W; Song J; Ma L; Hong Z; Hu J; Zhou G
    Med Sci Monit; 2020 Jun; 26():e922662. PubMed ID: 32532951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrastructural and ultracytochemical differences between megakaryoblastic leukemia in children and adults. Analysis of 49 patients.
    Eguchi M; Ozawa T; Sakakibara H; Sugita K; Iwama Y; Furukawa T
    Cancer; 1992 Jul; 70(2):451-8. PubMed ID: 1319816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemic blasts with markers of four cell lineages in Down's syndrome ("megakaryoblastic leukemia").
    Slørdahl SH; Smeland EB; Holte H; Grønn M; Lie SO; Seip M
    Med Pediatr Oncol; 1993; 21(4):254-8. PubMed ID: 8469219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia With Unusual Immunophenotype.
    Koulmane Laxminarayana SL; Kohli S; Agrohi J; Belurkar S
    Cureus; 2023 Mar; 15(3):e35965. PubMed ID: 36911590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
    Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
    Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
    Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
    Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics.
    Panda D; Chatterjee G; Sardana R; Khanka T; Ghogale S; Deshpande N; Badrinath Y; Shetty D; Narula G; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2021 Mar; 100(2):206-217. PubMed ID: 32865882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Megakaryoblastic Leukemia Associated with Trisomy 21 Demonstrates a Distinct Immunophenotype.
    Wang L; Peters JM; Fuda F; Li L; Karandikar NJ; Koduru P; Wang H; Chen W
    Cytometry B Clin Cytom; 2014 Oct; ():. PubMed ID: 25302938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.
    Yamada S; Hongo T; Okada S; Watanabe C; Fujii Y; Hori H; Yazaki M; Hanada R; Horikoshi Y
    Int J Hematol; 2001 Dec; 74(4):428-36. PubMed ID: 11794699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute megakaryoblastic leukemia in Down syndrome.
    Hitzler JK
    Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase and the benign and malignant megakaryoblastic leukemias of Down syndrome.
    Holt SE; Brown EJ; Zipursky A
    J Pediatr Hematol Oncol; 2002 Jan; 24(1):14-7. PubMed ID: 11902731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.